Age ≥75 with ECOG ≥2 or ≥2 comorbidities — gemcitabine + cisplatin + durvalumab triplet p...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CHOLANGIOCARCINOMA-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-NCCN-HCC-2025 |
Red Flag Origin
| Definition | Age ≥75 with ECOG ≥2 or ≥2 comorbidities — gemcitabine + cisplatin + durvalumab triplet poorly tolerated; consider gemcitabine + cisplatin doublet, gemcitabine monotherapy, or best supportive care depending on biliary-tree dysfunction and performance status. |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"all_of": [
{
"comparator": ">=",
"finding": "age_years",
"threshold": 75
},
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 2
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
}
],
"type": "composite_clinical"
}
Notes
Historical notes contain a retired source reference. Consult the original YAML for audit history.
Used By
Indication
IND-CHOLANGIO-2L-FGFR2-FUSION-PEMIGATINIB- IND-CHOLANGIO-2L-FGFR2-FUSION-PEMIGATINIBIND-CHOLANGIO-2L-FUTIBATINIB- IND-CHOLANGIO-2L-FUTIBATINIBIND-CHOLANGIO-2L-HER2-ZANIDATAMAB- IND-CHOLANGIO-2L-HER2-ZANIDATAMABIND-CHOLANGIO-2L-IDH1-IVOSIDENIB- IND-CHOLANGIO-2L-IDH1-IVOSIDENIBIND-CHOLANGIO-2L-INFIGRATINIB- IND-CHOLANGIO-2L-INFIGRATINIB